Demonstrated safety profile for REXULTI® (brexpiprazole) in adults

Study 3 and Study 4: REXULTI—adverse reactions that occurred in ≥2%
of patients and greater incidence vs placebo from two 6-week pivotal trials

Study 3 and Study 4 adverse reactions REXULTI vs placebo Demonstrated safety profile Akathisia 6 % 5 % Weight increased 4 % 2 % 2 % Diarrhea Dyspepsia Tremor 1 % 1 % 3 % 2 % 3 % 2 % 3 % Blood creatinine phosphokinase increased 1 % 2 % Sedation Placebo (n=368) REXULTI (all doses) (n=852)

Study 3 and Study 4: REXULTI—
adverse reactions that occurred in ≥2%
of patients and greater incidence vs placebo from
two 6-week pivotal trials

Study 3 and Study 4 adverse reactions REXULTI vs placebo
  • Most common adverse reaction occurring in ≥4% of patients and at least twice the rate of placebo was weight increased
  • In both trials, akathisia occurred most often during the first 3 weeks of treatment, and no incidences resulted in treatment discontinuation1,2
  • The safety population included patients receiving 1 mg/day
 

Additional safety information across 2 pivotal trials

REXULTI—safety considerations evaluated over 6 weeks3

REXULTI safety considerations evaluated over 6 weeks Additional safety information P r olactin 3 Elect r oca r diog r am 5 % 4 % Did not p r olong the Q T c in t er v al t o a n y clinically r el ev ant e x t ent No clinically meanin g ful chan g es Placebo (n=368) REXULTI (all doses) (n=852)
REXULTI safety considerations evaluated over 6 weeks
 

REXULTI: Metabolic data across all doses in short- and long-term trials in adults

WEIGHT CHANGE

Weight change results across all doses4,5

Weight change results across all doses Metabolic profile weight change Placebo REXULTI 4%of patients 10%of patients 2%5of patients 2%5of patients 20%of patients 10%of patients REXULTI Weight change 7% increasein body weight 7% decreasein body weight Mean weight increased b 0.2 kg 4 1.2 kg 4 52 weeks 2.0 kg 26 weeks 1.3 kg 6-week, placebo-controlled, fixed-dose pivotal trials 52-week, open-label, flexible-dose trials a

aAfter the conclusion of the 6-week trial, patients who elected to remain in the trial, patients from the Phase 2 trial, and de novo patients were treated with flexible doses of REXULTI (1 mg to 6 mg) in a 52-week, open-label trial, and no placebo control was included. Safety data were collected at regular intervals throughout the 52 weeks. The overall N was 813; n values for individual parameters varied.6

bSD for mean weight increased at 6 weeks were 3.4 kg for REXULTI and 2.7 kg for placebo, at 26 weeks was 5.5 kg for REXULTI, and at 52 weeks was 7.3 kg for REXULTI.6,7

The standard conversion for kilograms (kg) to pounds (lb) is 1 kg for 2.20462 lb.

SD, standard deviation.

Discontinuation due to weight increased across all doses6,8

aAfter the conclusion of the 6-week trial, patients who elected to remain in the trial, patients from the Phase 2 trial, and de novo patients were treated with flexible doses of REXULTI (1 mg to 6 mg) in a 52-week, open-label trial, and no placebo control was included. Safety data were collected at regular intervals throughout the 52 weeks. The overall N was 813; n values for individual parameters varied.6

METABOLIC CHANGE

Percentage of patients whose values shifted from baseline to post-baseline6,9

Metabolic profile in short- and long-term trials Metabolic change Cholesterol Triglycerides Fasting serum glucose % of patients who shifted from: Similar rates between REXULTI and placebo Similar rates between REXULTI and placebo 6 % 6 2 % 6 17 % 6 13 % 6 0.4 % 6 0.6 % 6 10% REXULTI Placebo REXULTI 52-week, open-label, flexible-dose trials a 6-week, placebo-controlled, fixed-dose pivotal trials <150 mg/dL 200 to <500 mg/dL Normal High <150 mg/dL 500 mg/dL Normal Very High <150 mg/dL 150 to <200 mg/dL 500 mg/dL Normal Borderline Very High Fasting total cholesterol <200 mg/dL 240 mg/dL Normal High Fasting LDL cholesterol <100 mg/dL 160 mg/dL Normal High Fasting HDL cholesterol 40 mg/dL <40 mg/dL Normal Low 9 % 9 6 % 6 0.2 % 9 0 % 9 0 % 6 0.2 % 9 Normal Borderline High <100 mg/dL 100 to <126 mg/dL 126 mg/dL

Percentage of patients whose values shifted from baseline to post-baseline6,9

metabolic profile in short and long term trials

aAfter the conclusion of the 6-week trial, patients who elected to remain in the trial, patients from the Phase 2 trial, and de novo patients were treated with flexible doses of REXULTI (1 mg to 6 mg) in a 52-week, open-label trial, and no placebo control was included. Safety data were collected at regular intervals throughout the 52 weeks. The overall N was 813; n values for individual parameters varied.6

HDL, high-density lipoprotein; LDL, low-density lipoprotein.

Important Warning and Precaution for Metabolic Changes

Atypical antipsychotic drugs have been associated with metabolic changes that include Hyperglycemia/Diabetes Mellitus, Dyslipidemia, and Weight Gain. Clinical monitoring is recommended.

Continue exploring REXULTI

Review results from pivotal clinical trials for REXULTI.

Review results from
pivotal clinical trials for REXULTI.

Patient Profile

Consider a patient with
unresolved symptoms.

IMPORTANT SAFETY INFORMATION
and INDICATIONS

 
  • Use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults
  • Treatment of schizophrenia in adults and pediatric patients ages 13 years and older
  • Treatment of agitation associated with Alzheimer’s dementia (AAD)
ISI Block Title

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at increased risk of death. REXULTI is not approved for the treatment of patients with dementia-related psychosis without agitation associated with dementia due to Alzheimer’s disease.

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

Antidepressants increased the risk of suicidal thoughts and behaviors in patients aged 24 years and younger. Monitor for clinical worsening and emergence of suicidal thoughts and behaviors. The safety and effectiveness of REXULTI have not been established in pediatric patients with MDD.

Contraindication: In patients with known hypersensitivity to brexpiprazole or any of its components. Reactions have included: rash, facial swelling, urticaria and anaphylaxis.

Cerebrovascular Adverse Events, Including Stroke: In clinical trials, elderly patients with dementia randomized to risperidone, aripiprazole, and olanzapine had a higher incidence of stroke and transient ischemic attack, including fatal stroke. REXULTI is not approved for the treatment of patients with dementia-related psychosis without agitation associated with dementia due to Alzheimer’s disease.

Neuroleptic Malignant Syndrome (NMS): NMS is a potentially fatal symptom complex reported in association with administration of antipsychotic drugs, including REXULTI. Clinical signs of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia). Additional signs may include elevated creatinine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. Manage NMS with immediate discontinuation of REXULTI, intensive symptomatic treatment, and monitoring.

Tardive Dyskinesia (TD): Risk of TD, and the potential to become irreversible, appear to increase with duration of treatment and total cumulative dose of antipsychotic drugs. TD can develop after relatively brief treatment periods, at low doses, or after discontinuation of treatment. For chronic treatment, use the lowest dose and shortest duration of REXULTI needed to produce a clinical response. If signs and symptoms of TD appear, drug discontinuation should be considered.

Metabolic Changes: Atypical antipsychotic drugs, including REXULTI, have caused metabolic changes including:

  • Hyperglycemia/Diabetes Mellitus: Hyperglycemia and diabetes mellitus, in some cases extreme and associated with diabetic ketoacidosis, hyperosmolar coma or death, have been reported in patients treated with atypical antipsychotics. Assess fasting plasma glucose before or soon after initiation of antipsychotic medication and monitor periodically during long-term treatment.
  • Dyslipidemia: Atypical antipsychotics cause adverse alterations in lipids. Before or soon after initiation of antipsychotic medication, obtain a fasting lipid profile at baseline and monitor periodically during treatment.
  • Weight Gain: Weight gain has been observed in patients treated with REXULTI. Monitor weight at baseline and frequently thereafter.

Pathological Gambling and Other Compulsive Behaviors: Intense urges, particularly for gambling, and the inability to control these urges have been reported while taking REXULTI. Other compulsive urges have been reported less frequently. Prescribers should ask patients or their caregivers about the development of new or intense compulsive urges. Consider dose reduction or stopping REXULTI if such urges develop.

Leukopenia, Neutropenia, and Agranulocytosis: Leukopenia and neutropenia have been reported with antipsychotics. Agranulocytosis (including fatal cases) has been reported with other agents in this class. Monitor complete blood count in patients with pre-existing low white blood cell count (WBC)/absolute neutrophil count or history of drug-induced leukopenia/neutropenia. Discontinue REXULTI at the first sign of a clinically significant decline in WBC and in patients with severe neutropenia.

Orthostatic Hypotension and Syncope: Atypical antipsychotics cause orthostatic hypotension and syncope. Generally, the risk is greatest during initial dose titration and when increasing the dose. Monitor in patients vulnerable to hypotension, and those with cardiovascular and cerebrovascular diseases.

Falls: Antipsychotics may cause somnolence, postural hypotension, motor, and sensory instability, which may lead to falls causing fractures or other injuries. For patients with diseases, conditions, or medications that could exacerbate these effects, complete fall risk assessments when initiating treatment and recurrently during therapy.

Seizures: REXULTI may cause seizures and should be used with caution in patients with a history of seizures or with conditions that lower the seizure threshold.

Body Temperature Dysregulation: Use REXULTI with caution in patients who may experience conditions that increase body temperature (e.g., strenuous exercise, extreme heat, dehydration, or concomitant use with anticholinergics).

Dysphagia: Esophageal dysmotility and aspiration have been associated with antipsychotics, including REXULTI, and should be used with caution in patients at risk for aspiration.

Potential for Cognitive and Motor Impairment: REXULTI has the potential to impair judgment, thinking, or motor skills. Patients should be cautioned about operating hazardous machinery, including operating motor vehicles, until they are reasonably certain REXULTI does not affect them adversely.

Concomitant Medication: Dosage adjustments are recommended in patients who are known cytochrome P450 (CYP) 2D6 poor metabolizers and in patients taking concomitant CYP3A4 inhibitors or CYP2D6 inhibitors or strong CYP3A4 inducers.

Most commonly observed adverse reactions: In clinical trials of adults, the most common adverse reactions were:

  • Major Depressive Disorder (MDD) (adjunctive treatment to antidepressant therapy; ≥5% incidence and at least twice the rate of placebo for REXULTI vs. placebo): weight increased, somnolence, and akathisia.
  • Schizophrenia (≥4% incidence and at least twice the rate of placebo for REXULTI vs. placebo): weight increased. Adverse reactions in patients 13 to 17 years of age were generally similar to those observed in adult patients.
  • Agitation associated with dementia due to Alzheimer’s disease (≥4% incidence and at least twice the rate of placebo for REXULTI vs. placebo): nasopharyngitis and dizziness.

Dystonia: Symptoms of dystonia may occur in susceptible individuals during the first days of treatment and at low doses.

Pregnancy: Adequate and well-controlled studies to assess the risks of REXULTI during pregnancy have not been conducted. REXULTI should be used during pregnancy only if the benefit justifies the risk to the fetus.

Lactation: It is not known if REXULTI is excreted in human breast milk. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

To report SUSPECTED ADVERSE REACTIONS, contact Otsuka America Pharmaceutical, Inc. at 1-800-438-9927 or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch).

INDICATIONS

REXULTI is indicated for:

  • Use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults
  • Treatment of schizophrenia in adults and pediatric patients ages 13 years and older
  • Treatment of agitation associated with dementia due to Alzheimer’s disease

Limitations of Use: REXULTI is not indicated as an as needed (“prn”) treatment for agitation associated with dementia due to Alzheimer’s disease

Please see FULL PRESCRIBING INFORMATION, including BOXED WARNING.